Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: Impact on treatment outcomes and implications for tuberculosis control

AIDS

Volumn 20, Issue 12, 2006, Pages 1605-1612

  Lawn, Stephen D ^a,b,d   Myer, Landon ^a,c   Bekker, Linda Gail ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Columbia University ^*  (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antiretroviral programme; HAART; HIV; Resource limited country; TB control; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; EFAVIRENZ; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COST OF ILLNESS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PREVALENCE; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 33746715037     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000238406.93249.cd     Document Type: Article

References (27)

1. WHO/UNAIDS. Progress of Global Access to HIV Antiretroviral Therapy. An Update on '3 by 5'. Geneva: WHO/UNAIDS; June 2005. Accessed 19 October 2005: http://www.who.int/hiv/pub/progressreports/3by5%20Progress%20Report_E_light. pdf-.
2. Corbett EL, Marston B, Churchyard GJ, de Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926-937.
3. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006; 42:1040-1047.
4. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75-80.
5. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
6. de Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med 2004; 55:283-301.
7. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
8. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
9. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-2064.
10. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301:1535-1537.
11. Lawn SD, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis 2005; 41:1783-1786.
12. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172:123-127.
13. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
14. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006; 6:59.
15. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and non-death losses from an antiretroviral treatment service in South Africa: implications for programme evaluation. Clin Infect Dis 2006; in press.
16. Health Systems Trust. Cape Town TB Control: Progress Report 1997-2003. Cape Town: Health Systems Trust; 2004. www.hst.org.za.
17. World Health Organization. Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach; Executive Summary. Geneva: World Health Organization; 2002. Accessed 15 April 2005: http://www.who.int/hiv/pub/prev-care/en/WHO_ARV_Guidelines.pdf.
18. Orrell C, Badri M, Wood R. Measuring adherence in a community setting: which measure is most valuable? XV International Conference on AIDS, Bangkok, July 2004 [abstract WePEB5787].
19. Cuzick JA. Wilcoxon-type test for trend. Stat Med 1985; 4:87-90.
20. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. Oxford: Oxford University Press and International Agency for Research on Cancer; 1987.
21. Diggle P, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford: Oxford University Press; 1994.
22. Lawn SD, Myer L, Wood R. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world? Clin Infect Dis 2005; 41:1683-1684.
23. Lawn SD, Wood R. How can earlier entry of patients into antiretroviral programs in low-income countries be promoted? Clin Infect Dis 2006; 42:431-432.
24. Moore D, Ekwaru P, Liechty C, Were W, Mwima G, Solberg P, et al. Prevalence, incidence and outcomes of tuberculosis treatment in HIV+ individuals initiating home-based antiretroviral therapy in rural Uganda. 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 2006 [abstract 794].
25. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113-1124.
26. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195.
27. Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-161.